Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

t of the ASCEND trial, which was initiated in July 2011.  

Selling, general and administrative (SG&A) expenses were $23.8 million in the third quarter of 2012, relatively unchanged from $23.7 million in the same quarter of 2011.  SG&A expenses were $75.7 million in the first nine months of 2012, an increase of 21 percent from $62.7 million in the comparable nine-month period of 2011.  The increased spending for the nine-month period in 2012, compared with the same period in 2011, is primarily attributable to the creation of InterMune's European infrastructure and investments in the launch and pre-launches of Esbriet in Germany and other European countries.

Net loss for the third quarter of 2012 was $45.4 million, or $0.70 per share, compared with a net loss of $38.2 million, or $0.63 per share, in the same quarter of 2011.  Net loss for the first nine months of 2012 was $91.5 million, or $1.41 per share, compared with a net loss of $110.2 million, or $1.88 per share, in the first nine months of 2011.  Per share amounts in the first nine months included gains from the role of Actimmune® (interferon gamma-1b) in discontinued operations of $0.82 per share and $0.14 per share in 2012 and 2011, respectively.As a result of the June 19, 2012 divestiture of Actimmune, historical Actimmune revenue, cost of goods sold and operating costs are reported in discontinued operations in this and future financial statements and therefore do not appear in the comparisons above regarding on-going operations.

As of September 30, 2012, InterMune had cash, cash equivalents and available-for-sale securities of approximately $351.4 million.

Guidance for 2012 Revenue and Expenses
Considering the proximity to year-end 2012, the company today provided greater precision regarding its forward-looking guidance for Esbriet revenue and operating expense guidance for 2012:

  • Esbriet revenue: currently anticipat
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
    (Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
    (Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
    (Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
    Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
    ... , , ... Q4 and full-year results today with CEO David,Brennan saying ... restructuring had helped deliver a revenue line above company,expectations. , ... results and the drivers behind a 23%,rise in core operating profit ...
    ... ... that allows researchers to build nano-sized structures out of DNA (or RNA). To help illustrate ... allows users to build virtual nanostructures by sequencing a simple, abstract representation of a DNA ... ...
    ... , , SAO PAULO , ... Commission to propose additional out-of-quota sugar exports for an,amount of ... on the Commission for a cautious approach, taking into,consideration all ... According to UNICA, the European Commission is sending ...
    Cached Biology Technology:AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009 2Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Cautious Approach Needed Before Any Decision on EU Out-of-Quota Sugar Exports Is Taken 2
    (Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
    (Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
    Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
    ... ear of a tropical butterfly that potentially makes it able ... discovered by scientists from the University of Bristol, UK. ... associated with the detection of predators, in particular birds. ... Central and South America, are more famous for their amazing ...
    ... knee joints might one day be repaired with cartilage grown ... Professor Kyriacos Athanasiou, chair of the UC Davis Department of ... from bone marrow and skin as well as human embryonic ... tissue in the lab. Now they are experimenting with various ...
    ... were the key to the end of the dinosaurs, ... and ecotoxicologist John H. Rodgers have published findings that ... extinctions millions of years ago. The research not only ... a caution about the future. The scientists say that ...
    Cached Biology News:Clemson researchers say algae key to mass extinctionss 2
    All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
    adult...
    DNA Purification...
    Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
    Biology Products: